Press Releases

Oncology Market Size is Forecasted to Hit Around US$ 581.25 Billion by 2030

The global oncology market size is forecasted to hit from US$ 286.04 billion in 2021 to US$ 286.04 billion by 2030 and is anticipated to grow at compounded annual growth rate (CAGR) of 8.2% from 2021 to 2030, as per reports by market research and consulting organization Precedence Research.

The report contains 150+ pages with detailed analysis. The base year for the study has been considered 2021, the historic year 2017 to 2020, the forecast period considered is from 2021 to 2030. The oncology market is analyzed on the basis of value (US$ Million), volume (Unit), and price (US$/Unit). The report offers exclusive insights to help companies make informed decisions to sustain growth through the assessment period.

Download Free Sample Copy with TOC, Graphs & List of Figures @ https://www.precedenceresearch.com/sample/1467

The global oncology market is driven by the rising prevalence of cancer disease among the global population that significantly fosters the demand for the various oncology diagnostics and treatment products. Around 10 million cancer deaths were recorded in 2020 and around 19.3 million new cancer cases were diagnosed globally in 2020, as per the data provided by the International Agency for Research on Cancer in its report named GLOBOCAN.

The rising awareness regarding cancer and availability of various oncology treatment and innovative diagnostic tools for detecting cancer. The rising investments by the biopharmaceutical industry players in the research and clinical trials of various therapeutics and diagnostics are expected to fuel the growth of the global oncology market during the forecast period.

Scope of the Oncology Market

Report Coverage Details
Market Size in 2021 US$ 286.04 Billion
Growth Rate CAGR of 8.2% from 2021 to 2030
Largest Market North America
Fastest Growing Market Europe
Base Year 2021
Forecast Period 2021 to 2030
Segments Covered Cancer Diagnostics & Treatment, Indication, Region

Competitive Intelligence

The report provides an understanding of the market composition and explains the role of established players and regional contributors. It is essential for the market players to make calculative moves and focus on client acquisition and retention. The detailed company profiles will provide the necessary intelligence to the reader. In order to maintain their share, the market players are focusing on strategies such as cross-border expansion, product differentiation and so on.

Some of the prominent players in the global oncology market are listed as below:

  • Aegerion Pharmaceuticals Inc.
  • Abbvie Inc.
  • Ability Pharma
  • Acadia Pharmaceuticals Inc.
  • Amgen Inc.
  • Takeda Oncology
  • Aslan Pharmaceuticals Ltd.
  • Aspen Pharmacare Holdings Limited.
  • Astrazeneca
  • Athenex, Inc.

Market Dynamics

Driver

Rapidly rising prevalence of cancer across the globe

As per the IARC, the global new cancer cases is expected to rise by 47% from 2020 to 2040. Therefore, the projected increase in the new cancer cases by almost 50% in a span of 20 years is a major factor that will play a crucial role in spurring the demand for the oncology diagnostics and treatment across the globe. The rapidly growing pharmaceutical industry is expected to boost the oncology market growth in the forthcoming years. Moreover, the increasing adoption of the immunotherapy and targeted therapy owing to their effectiveness and low complications is spurring the growth of the oncology market.

Restraints

Lack of awareness and low access to healthcare facilities

There is a lack of awareness in the underdeveloped and developing economies regarding cancer. Most of the people remain undiagnosed owing to the low financial capabilities and poor access to the healthcare services and other facilities. This is a major factor that may hinder the growth of the global oncology market during the forecast period. The lack of adequate healthcare infrastructure is depriving the people from acquiring the necessary treatment and diagnostics related to cancer and various other chronic diseases.

Opportunities

Technological advancements in the diagnostics

The increasing awareness among the population regarding cancer and availability of various cancer diagnostic devices is expected to fuel the market growth. Moreover, the increased affordability and rising healthcare expenditure coupled with the desire to detect cancer disease in the early stages is significantly driving the growth of the oncology market.

Challenges

The presence of alternatives to the oncology treatment

The rapidly growing usage of biosimilar is a major threat to the oncology market. The biosimilar such as etanercept, infliximab, and rituximab are being extensively used in the treatment of cancer. Moreover, the approval of the FDA and EMA for the use of biosimilar has helped it to gain the confidence of the consumers in the past few years. Therefore, the presence of biosimilar is a major threat to the global oncology market.

Report Highlights

  • Based on the cancer diagnostics & treatment, the cancer treatment segment dominated the oncology market, garnering a market share of around 56% in 2020. The rising adoption of the targeted therapy and the immunotherapy for the treatment of cancer is exponentially spurring the growth of the cancer treatment segment. The low side effects and effective cancer treatment are the major advantages of the latest therapies over the traditional chemotherapy that is fostering the growth of this segment.
  • Based on the indication, the breast cancer is estimated to be the most opportunistic segment during the forecast period. This is mainly due to the alarming rise in the breast cancer cases across the globe. According to the IARC, around 2.3 million new breast cancer cases were reported in 2020 all over the globe.

Regional Snapshot

North America accounted for around 46% of the market share in 2020 and dominated the global oncology market. The increased prevalence of cancer in the region coupled with the increased healthcare expenditure is augmenting the demand for the oncology treatment. Moreover, the increasing awareness regarding the various treatment and diagnostics related to cancer is expected to spur the growth of the market. The rapidly growing prevalence of various types of cancer such as lungs cancer, breast cancer, prostate cancer, and colorectal cancer in US has exponentially contributed in the growth of the oncology market.According to the American Cancer Society, over 1.8 million new cancer cases and 606,520 deaths were reported in the US in 2020.

Europe is expected to be the fastest-growing market during the forecast period. The constantly rising cases of cancer and cancer deaths across the European countries is the major reason behind the burgeoning growth of the Europe oncology market.Around 2.7 million new cancer cases and about 1.3 million cancer deaths were recorded in 2020 in Europe, as per the European Commission. Moreover, the breast cancer was the most diagnosed cancer type across the European nations in 2020. Increased demand for the advanced and innovative technologies in the healthcare industry in Europe is estimated to be the major driving force of the oncology market in Europe.

Segments Covered in the Report

By Cancer Diagnostics & Treatment

  • Cancer Diagnostics
    • Biopsy
    • Imaging
    • Immunohistochemistry
    • Tumor Biomarkers Test
    • In Situ Hybridization
    • Liquid Biopsy
  • Cancer Treatment
    • Targeted Therapy
    • Chemotherapy
    • Hormonal Therapy
    • Immunotherapy
    • Others

By Indication

  • Lungs Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Liver Cancer
  • Bladder Cancer
  • Head & Neck Cancer
  • Prostate Cancer
  • Others

Regional Segmentation

– North America (U.S. and Canada)

 – Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)

 – Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)

 – Latin America (Brazil and Rest of Latin America)

– Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Why should you invest in this report?

If you are aiming to enter the global oncology market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for oncology are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Buy Full Research Report, Click Here@ https://www.precedenceresearch.com/checkout/1467

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Oncology Market 

5.1. COVID-19 Landscape: Oncology Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Oncology Market, By Indication

8.1. Oncology Market, by Indication Type, 2021-2030

8.1.1. Lungs Cancer

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. Colorectal Cancer

8.1.2.1. Market Revenue and Forecast (2019-2030)

8.1.3. Breast Cancer

8.1.3.1. Market Revenue and Forecast (2019-2030)

8.1.4. Liver Cancer

8.1.4.1. Market Revenue and Forecast (2019-2030)

8.1.5. Bladder Cancer

8.1.5.1. Market Revenue and Forecast (2019-2030)

8.1.6. Head & Neck Cancer

8.1.6.1. Market Revenue and Forecast (2019-2030)

8.1.7. Prostate Cancer

8.1.7.1. Market Revenue and Forecast (2019-2030)

8.1.8. Others

8.1.8.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Oncology Market, By Cancer Diagnostics & Treatment

9.1. Oncology Market, by Cancer Diagnostics & Treatment, 2021-2030

9.1.1. Cancer Diagnostics (Biopsy, Imaging, Immunohistochemistry, Tumor Biomarkers Test, In Situ Hybridization, Liquid Biopsy)

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Cancer Treatment (Targeted Therapy, Chemotherapy, Hormonal Therapy, Immunotherapy, Others)

9.1.2.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Oncology Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Indication (2019-2030)

10.1.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Indication (2019-2030)

10.1.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Indication (2019-2030)

10.1.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Indication (2019-2030)

10.2.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Indication (2019-2030)

10.2.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Indication (2019-2030)

10.2.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Indication (2019-2030)

10.2.5.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Indication (2019-2030)

10.2.6.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Indication (2019-2030)

10.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Indication (2019-2030)

10.3.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Indication (2019-2030)

10.3.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Indication (2019-2030)

10.3.5.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Indication (2019-2030)

10.3.6.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Indication (2019-2030)

10.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Indication (2019-2030)

10.4.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Indication (2019-2030)

10.4.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Indication (2019-2030)

10.4.5.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Indication (2019-2030)

10.4.6.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Indication (2019-2030)

10.5.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Indication (2019-2030)

10.5.3.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Indication (2019-2030)

10.5.4.2. Market Revenue and Forecast, by Cancer Diagnostics & Treatment (2019-2030)

Chapter 11. Company Profiles

11.1. Aegerion Pharmaceuticals Inc.

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Abbvie Inc.

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Ability Pharma

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Acadia Pharmaceuticals Inc.

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Amgen Inc.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Takeda Oncology

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Aslan Pharmaceuticals Ltd.

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Aspen Pharmacare Holdings Limited.

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Astrazeneca

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Athenex, Inc.

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1467

Contact Us:         

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Show More

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

Related Articles

Back to top button